Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 231-104-6 | CAS number: 7439-95-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Exposure related observations in humans: other data
Administrative data
- Endpoint:
- exposure-related observations in humans: other data
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- supporting study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Well conducted study, meets general scientific principles.
Data source
Reference
- Reference Type:
- publication
- Title:
- Urinary and Fecal Excretion of Orally Administered Mg28
- Author:
- Aikawa JK, Rhoades EL & Gordon GS
- Year:
- 1 958
- Bibliographic source:
- Proc. Soc. Exp. Biol. Med., 98(1): 29-31
Materials and methods
- Type of study / information:
- behaviour of orally administered magnesium, using Mg28 as tracer. Urinary and faecal excretion of the isotope was measured.
- Endpoint addressed:
- basic toxicokinetics
Test guideline
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- The purpose of the study was to follow the behaviour of orally administered magnesium, using Mg28 as tracer. Urinary and faecal excretion of the isotope was measured.
- GLP compliance:
- no
Test material
- Reference substance name:
- Magnesium chloride
- EC Number:
- 232-094-6
- EC Name:
- Magnesium chloride
- Cas Number:
- 7786-30-3
- IUPAC Name:
- magnesium dichloride
- Test material form:
- solid: compact
- Details on test material:
- Radioactive magnesium (Mg28) as magnesium chloride
Constituent 1
Method
- Ethical approval:
- not specified
- Details on study design:
- Initial observations (Group A) were made in 12 hospitalised adult male convalescents from various diseases. None had any symptoms or signs of gastrointestinal disturbances and all were on regular hospital diet.
- Exposure assessment:
- measured
- Details on exposure:
- Radioactive magnesium (Mg28) as magnesium chloride in an acid solution, was given in water, usually mid-morning. The doses of 10 to 25 µC was contained in 3 to 10 meq of magnesium.
All urine passed within the next 24 hours was collected in chemically clean glassware.
7 patients were given one dose of Mg28; 4 were given 2 doses a week apart and the 12th patient given 3 doses of tracer at weekly intervals.
Subsequent studies (Groups B, C and D) were done in 14 healthy medical students. Each student received orally 10 µC of Mg28 contained in 3 meq of magnesium. In 7 instances (Groups C and D), 2 gelatin capsules containing a gram of carmine were given at the same time. In addition to specimens of urine and faeces collected in chemically clean glassware from all students, several venous blood specimens were obtained from 3 students in Group D. 2 students (#11 and 12) were given a second dose of isotope one week after the first.
Radioactivity of urine, plasma and faeces was determined with a well-type scintillation counter and a scaling circuit. Stool specimens were digested in concentration sulfuric acid and nitric acids prior to radioactivity assay. A total of 10,000 counts were made on each sample. All determinations were corrected for physical decay of isotope.
Results and discussion
- Results:
- The maximum 24 hour urinary excretion rate for Mg28 in hospitalised patients (Group A) was 6.27%; the mean was 2.11 ± 1.61%. Except in one patient, the second and third determinations of urinary excretion rate gave results closely comparable to the first.
The 24 hour urinary excretion of radioactivity in the first 9 medical students (Group B) was between 1.13 and 4.93% of total administered dose, mean value being 2.88 ± 1.27%. Maximum total radioactivity recovered in stools within the first 48 hours was 61.85%.
Four other students (Group C) were then given, in addition to the same dose of Mg28, the carmine indicator. Stools were collected for 96 hours or until the red colour had disappeared. Urine specimens were collected for 48 hours. Urinary excretion of radioactivity during the first 24 hours was comparable to that observed in Groups A and B; excretion of Mg28 during the second 24-hour period was consistently lower than that during the first 24 hours. Maximum faecal recovery rate obtained in this group was 85.16%. Radioactivity was usually greatest in stools with most intense red colour.
In the final set of observations (Group D), 3 students were given the same tracer dose of Mg28 and the carmine dye but urine collections were extended over 72 hours and faecal collections through 120 hours. Urinary excretion of Mg28 during the first 48 hours was comparable to that observed in Group C; amount of Mg28 excreted during 48-72 hour period was lower than that observed in either of the preceding 24 hour periods. Maximum % of radioactivity recovered in stools was 87.97%. In one subject, 96% of radioactivity was recovered in stool and urine.
Blood specimens were obtained at 2,4,6 and 8 hours after oral administration of Mg28 to 3 students in Group D. Calculations based on specific activity of material administered showed that rise in serum magnesium concentration attributable to orally administered material was in the order of 0.75 to 3.85 x 10-5 meq/L; the highest concentration in each subject was found at 4 hours.
Any other information on results incl. tables
Table 1: Urinary and faecal excretion of Mg28 following oral administration
Patient No. |
% of dose recovered in urine |
% of dose recovered in stool |
||||||||
0-24 h |
24-48 h |
48-72 h |
Total |
0-24 h |
24-48 h |
48-72 h |
72-96 h |
96-120 h |
Total |
|
Medical students |
||||||||||
Group C |
||||||||||
10 |
2.87 |
1.77 |
- |
- |
60.13 |
14.48 |
0.65 |
- |
- |
75.26 |
11-1 |
4.27 |
2.72 |
- |
- |
0.10 |
7.16 |
35.26 |
42.64 |
- |
85.16 |
12-1 |
2.17 |
1.55 |
- |
- |
24.34 |
26.46 |
- |
24.45 |
- |
75.25 |
13 |
1.71 |
1.14 |
- |
- |
0 |
45.66 |
4.11 |
6.56 |
- |
56.33 |
Mean |
2.76 |
2.39 |
- |
- |
- |
- |
- |
- |
- |
|
Group D |
||||||||||
11-2 |
3.18 |
2.02 |
1.05 |
6.25 |
0.22 |
1.56 |
11.67 |
32.26 |
37.08 |
82.79 |
12-2 |
3.98 |
3.28 |
0.91 |
8.17 |
1.14 |
25.30 |
- |
- |
61.53 |
87.97 |
14 |
1.24 |
1.80 |
0.17 |
3.21 |
41.62 |
14.28 |
3.50 |
- |
- |
59.40 |
Mean |
2.80 |
2.37 |
0.71 |
- |
- |
- |
- |
- |
- |
- |
Table 2: Plasma radioactivity concentration following oral administration of Mg28
Subject |
Hours after oral ingestion |
|||
2 |
4 |
6 |
8 |
|
11-2 |
1.05* |
3.85 |
3.46 |
2.73 |
12-2 |
1.10 |
2.26 |
1.96 |
1.07 |
14 |
0.75 |
1.12 |
1.09 |
- |
* all values = x 10-5meq/L and are based on specific activity of the material administered
Applicant's summary and conclusion
- Conclusions:
- Urinary excretion within 72 hours accounted for less than 10% of the total dose of Mg28; the maximal excretion (6.3%) occurred during the first 24 hour period. Maximal concentration of radioactivity in plasma occurred at 4 hours but the actual increase in serum magnesium was negligible. Faecal excretion within 120 hours accounted for 60 to 88% of administered dose. Low renal excretion of magnesium is believed to be due to poor gastrointestinal absorption of this material.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.